AEterna Zentaris (TSX:AEZS) Institutional Ownership : 0.08% (As of Apr. 24, 2024)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AEterna Zentaris's institutional ownership is 0.08%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AEterna Zentaris's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AEterna Zentaris's Float Percentage Of Total Shares Outstanding is 99.70%.

AEterna Zentaris Institutional Ownership Historical Data

The historical data trend for AEterna Zentaris's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Institutional Ownership Chart

AEterna Zentaris Historical Data

The historical data trend for AEterna Zentaris can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08

AEterna Zentaris Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.